HYHizbillah Yazid

Hizbillah Yazid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hizbillah Yazid has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Arif Zulkarnain

    Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Orthopedics and Traumatology, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

    2 shared publications
  • Tri Wahyu Martanto

    Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Indonesia

    2 shared publications
  • Agus Kresnadi

    Airlangga University/Dr. Soetomo General Academic Hospital, Department of Orthopaedic and Traumatology, Surabaya, Indonesia

    1 shared publication
  • Dwikora Novembri Utomo

    Department of Orthopaedics and Traumatology, Faculty of Medicine, Airlangga University, Surabaya 60286, Indonesia

    1 shared publication
  • I Putu Alit Pawana

    Department of Physical Medicine and Rehabilitation, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, East Java, 60286

    1 shared publication
  • Komang Agung Irianto

    Staff of Orthopaedic and Traumatology Department, Faculty of Medicine, Universitas Airlangga, Dr Soetomo General Hospital, Surabaya

    1 shared publication

Latest Publications

  • Open Access

    Early outcomes of closed reduction followed by double spica casting and gait assessment in children aged 18–48 months with developmental dysplasia of the hip

    by Sufandi Fahmi, Tri Wahyu Martanto, Dwikora Novembri Utomo, Arif Zulkarnain, Hizbillah Yazid, I Putu Alit Pawana

  • Open Access

    The Role of Denosumab and Bisphosphonate in Osteogenesis Imperfecta: A Literature Review

    by Agus Kresnadi, Tri Wahyu Martanto, Arif Zulkarnain, Hizbillah Yazid

    Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by brittle bones and susceptibility to fractures. Management of OI focuses on minimizing fractures and improving bone strength. Denosumab and bisphosphonates have emerged as potential therapeutic agents in OI management due to their ability to modulate bone turnover. This literature review aims to explore the role of denosumab and bisphosphonates in the treatment of OI, highlighting their mechanisms of action, efficacy, and safety profiles. A comprehensive search was conducted across various databases, to identify relevant studies investigating the use of denosumab and bisphosphonates in OI management. The review discusses the molecular pathways underlying the pathogenesis of OI and how denosumab and bisphosphonates intervene in these pathways to improve bone quality. Furthermore, the review summarizes the findings from clinical trials and observational studies evaluating the effectiveness of denosumab and bisphosphonates in reducing fracture rates, improving bone mineral density, parathyroid hormone changes, calcium and phosphate quantity, and also enhancing functional outcomes in patients with OI. Additionally, considerations regarding optimal dosing, timing of initiation, and potential adverse effects of denosumab and bisphosphonates in individuals with OI are discussed. The synthesis of existing evidence underscores the promising role of denosumab and bisphosphonates as adjunctive therapies in the management of OI, although further research is warranted to elucidate their long-term efficacy and safety profiles in this patient population


  • Open Access

    CONGENITAL SCOLIOSIS: AN ARTICLE REVIEW

    by Komang Agung Irianto, Hizbillah Yazid

    Background: Congenital Scoliosis (CS) defined as vertebral lateral deviation which forms during the intrauterine embryonic phase, carrying incidence between 0,5-1 per 1000 births. Mortality rate increases in untreated case, especially due to pulmonary problem (40%).Contents: CS can range from hemivertebrae (HV) which may be single or multiple, vertebral bar with or without HV, block vertebrae, wedge shaped or butterfly vertebrae. The risk factors for progression include: type of defect, site of defect, and the patient’s age. Plain radiographs remain standard diagnosis. MRI evaluation should be considered. The goal of managing CS is to obtain a balanced trunk and spine while maintaining as much normal spinal growth as possible and preventing neural deficit. Non-operative management is including observation, brace, and traction. The operative procedures are broadly divided into (a) those preventing further deformity: in situ fusion, convex hemiepiphysiodesis, and HV excision, (b) those that correct the present deformity: hemiepiphyseodesis & hemiarthrodesis, single & dual growing rods, HV excision, and reconstructive osteotomy.Conclusion: The treatment of CS remains one of the more challenging aspects of pediatric orthopaedic surgery. Operative treatment should be reserved for patients whom non-operative management didn’t meet the criteria or failed.